Separate from all that, however, it is persistent, long-term activation of Nrf2 that seems to protect cancer cells from genotoxic chemo- and radiotherapies, and to make them refractory to treatment, not controlled, intermittent activation from a small molecule Nrf2 inducer like RRx-001 (43). Here, NFE2L2 is linked to cancer.